Wide Ranks

CUE

Cue Biopharma, Inc.

1.22

Top Statistics
Market Cap 77 M Forward PE -2.14 Revenue Growth 92.30 %
Current Ratio 2.06 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.8760 Enterprise / Revenue 5.04 Price To Sales Trailing12 Months 9.32
Profitability
Profit Margins 0.00 % Operating Margins -390.63 %
Balance Sheet
Total Cash 30 M Total Cash Per Share 0.6170 Total Debt 11 M
Total Debt To Equity 52.09 Current Ratio 2.06 Book Value Per Share 0.7850
All Measures
Short Ratio 154.00 % Message Board Id finmb_417883814 Shares Short Prior Month 3 M
Return On Equity -1.39 City Boston Uuid 13b1e122-c7bb-3180-b359-74c89c132432
Previous Close 1.09 First Trade Date Epoch Utc 1 B Book Value 0.7850
Beta 1.80 Total Debt 11 M Volume 402071
Price To Book 1.55 Fifty Two Week Low 0.4500 Total Cash Per Share 0.6170
Total Revenue 8 M Shares Short Previous Month Date 1 B Target Median Price 4.00
Audit Risk 3 Max Age 86400 Recommendation Mean 1.40
Sand P52 Week Change 0.3133 Operating Margins -390.63 % Target Mean Price 3.60
Net Income To Common -46957000 Short Percent Of Float 0.0298 Implied Shares Outstanding 63 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 687680
Average Volume10days 687680 Total Cash 30 M Next Fiscal Year End 1 B
Revenue Per Share 0.1720 Held Percent Insiders 0.0055 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 4
Regular Market Previous Close 1.09 Target Low Price 2.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 1.22 Open 1.09 Free Cashflow -19995250
State MA Dividend Yield 0.00 % Return On Assets -0.5211
Time Zone Short Name EST Board Risk 9 Trailing Eps -0.9100
Day Low 1.08 Address1 40 Guest Street Shares Outstanding 63 M
Compensation Risk 8 Price Hint 4 Target High Price 6.00
Website https://www.cuebiopharma.com 52 Week Change -0.5120 Average Volume 758503
Forward Eps -0.5800 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 193.70 % Is_sp_500 False Regular Market Day High 1.25
Profit Margins 0.00 % Debt To Equity 52.09 Fifty Two Week High 3.25
Day High 1.25 Shares Short 1 M Regular Market Open 1.09
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 5.04
Revenue Growth 92.30 % Shares Percent Shares Out 0.0296 Operating Cashflow -38531000
Currency USD Time Zone Full Name America/New_York Market Cap 77 M
Is_nasdaq_100 False Zip 02135 Quote Type EQUITY
Industry Biotechnology Long Name Cue Biopharma, Inc. Overall Risk 7
Regular Market Day Low 1.08 Held Percent Institutions 0.2359 Current Price 1.22
Enterprise To Ebitda -0.8760 Financial Currency USD Current Ratio 2.06
Industry Disp Biotechnology Number Of Analyst Opinions 5 Country United States
Float Shares 48 M Two Hundred Day Average 1.35 Governance Epoch Date 1 B
Enterprise Value 41 M Price To Sales Trailing12 Months 9.32 Forward PE -2.14
Regular Market Volume 402071 Ebitda -47706000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body.

Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.

The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series.

It has collaboration agreements with LG Chem, Ltd.

for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co.

, Ltd.

to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine.

The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016.

Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.